# Phase 1/2 Lymphoma, B-Cell trials recruiting: 39 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 39 trials in phase 1/2 for Lymphoma, B-Cell that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 1/2 Lymphoma, B-Cell trials: 39 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-1-2/lymphoma-b-cell

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 39
- Recruiting or not yet: 39
- Read on: November 19, 2026

## Trials

The 25 newest of 39, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 29, 2026 | NCT07905261 | Clinical Study of SYS6055 Injection in Participants With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma | Beijing Kangchuanglian Biopharmaceutical Technology Research Co., Ltd | Phase 1/2 | Not yet recruiting | Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma | 384 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07905261) |
| July 30, 2026 | NCT07735533 | A Phase 1/2 Study of UB-VV400 With Rapamycin in Relapsed/Refractory B-cell Malignancies | Umoja Biopharma | Phase 1/2 | Recruiting | Lymphoma, B Cell, Lymphoma Non-Hodgkin, High Grade B Cell Lymphoma, Richter Transformation Lymphoma, Grade 3b... | 274 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07735533) |
| June 22, 2026 | NCT07658352 | A First-in-Human Study of HP-002 for Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma | Shanghai Helioson Pharmaceutical Co., Ltd. | Phase 1/2 | Not yet recruiting | B-Cell Non-Hodgkin Lymphoma | 114 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07658352) |
| May 13, 2026 | NCT07584889 | Efficacy and Safety of CD19-CAR.p40-T in Patients With Relapsed/Refractory CD19-Positive Hematologic Malignancies | Shenzhen University General Hospital | Phase 1/2 | Recruiting | B Cell Lymphoma, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07584889) |
| April 13, 2026 | NCT07523555 | Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies | Beijing Biotech | Phase 1/2 | Recruiting | Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia, Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL... | 96 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07523555) |
| April 9, 2026 | NCT07520006 | Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies | Nurix Therapeutics, Inc. | Phase 1/2 | Recruiting | B-cell Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07520006) |
| April 2, 2026 | NCT07508605 | Efficacy and Safety of CD19/CD20 CAR/TRuC-T in Relapsed/Refractory B-Cell Lymphoma | Shenzhen University General Hospital | Phase 1/2 | Recruiting | Relapsed/Refractory B-cell Lymphoma | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07508605) |
| April 2, 2026 | NCT07506668 | RN1701 Injection in the Treatment of Relapsed/Refractory B-Cell Lymphomas | Affiliated Hospital of Nantong University | Phase 1/2 | Not yet recruiting | Relapsed/Refractory B-cell Lymphoma | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07506668) |
| February 27, 2026 | NCT07439653 | A Study of TORL-5-700 in Relapsed/Refractory Non Hodgkin's Lymphoma | TORL Biotherapeutics, LLC | Phase 1/2 | Recruiting | Histologically Confirmed Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | 155 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07439653) |
| January 6, 2026 | NCT07319676 | Antigen Targeted T Cell Therapy for Relapsed/Refractory B Cell Lymphomas | National University Hospital, Singapore | Phase 1/2 | Recruiting | B-cell Lymphoma Refractory | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07319676) |
| December 16, 2025 | NCT07283679 | Trial of ONC-PluReceptor NK Cells With Epcoritamab and Tafasitamab for Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma | M.D. Anderson Cancer Center | Phase 1/2 | Recruiting | Recurrent B-Cell Non-Hodgkin Lymphoma, Refractory B-cell Non-Hodgkin Lymphoma | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07283679) |
| October 24, 2025 | NCT07220616 | A First-in-Human Trial of DS3790a in Participants With Hematological Malignancies | Daiichi Sankyo | Phase 1/2 | Recruiting | Hematological Malignancies, B-cell Non-Hodgkin Lymphoma | 420 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07220616) |
| August 14, 2025 | NCT07123454 | A Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory B-cell... | AstraZeneca | Phase 1/2 | Recruiting | B-cell Non-Hodgkin Lymphoma | 164 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07123454) |
| July 31, 2025 | NCT07097207 | Efficacy and Safety of CD19CD20-CAR.p40-T in B-cell Lymphoma | Shenzhen University General Hospital | Phase 1/2 | Recruiting | Relapsed/Refractory B-cell Lymphoma | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07097207) |
| June 6, 2025 | NCT07009002 | BCOR and ZC3H12 Genes Knock-out CD19-targeting CAR-T Cell Therapy in r/r B Cell Lymphoma | Chinese PLA General Hospital | Phase 1/2 | Recruiting | B Cell Lymphoma | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07009002) |
| May 23, 2025 | NCT06987916 | Efficacy and Safety Evaluation of U01(ssCART-19) in B-Cell Lymphoma | Shanghai Tongji Hospital, Tongji University School of Medicine | Phase 1/2 | Recruiting | B Cell Lymphoma | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06987916) |
| February 19, 2025 | NCT06834529 | CAR2219 CAR-T Cells for the Treatment of R/R B Cell Leukemia and Lymphoma | Affiliated Hospital to Academy of Military Medical Sciences | Phase 1/2 | Recruiting | Relapsed or Refractory B Cell Leukemia and Lymphoma | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06834529) |
| October 10, 2024 | NCT06634589 | A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed... | BeOne Medicines | Phase 1/2 | Recruiting | B-cell Malignancy, Relapsed Cancer, Refractory Cancer, B-cell Lymphoma | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06634589) |
| August 21, 2024 | NCT06564038 | A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies | AstraZeneca | Phase 1/2 | Recruiting | Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma, Mantle-cell Lymphoma, Large B-cell Lymphoma, B-cell... | 408 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06564038) |
| April 22, 2024 | NCT06378190 | Treatment of Relapsed or Refractory B-cell Lymphoma With Chimeric Antigen Receptor (CAR) T-cell Therapy Produced by a New Technology | Instituto de Investigación Biomédica de Salamanca | Phase 1/2 | Recruiting | Refractory B-Cell Lymphoma, B-cell Lymphoma Recurrent | 27 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06378190) |
| April 2, 2024 | NCT06343311 | T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) | Estrella Immunopharma, Inc. | Phase 1/2 | Recruiting | B-Cell Non-Hodgkin's Lymphoma (NHL), Lymphoma, Non-Hodgkins, Lymphomas Non-Hodgkin's B-Cell, Non-Hodgkin Lymphoma... | 27 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06343311) |
| January 19, 2024 | NCT06213636 | Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL). | Essen Biotech | Phase 1/2 | Recruiting | Acute Lymphoblastic Leukemia, Adult B-Cell, Acute Lymphoblastic Leukemia, in Relapse, Non-Hodgkin Lymphoma, B-cell... | 75 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06213636) |
| September 21, 2023 | NCT06045910 | A Phase I/II Trial of ALETA-001 for the Treatment of Participants With B-cell Malignancies | Cancer Research UK | Phase 1/2 | Recruiting | Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell, Lymphoma, Follicular, Lymphoma, B-Cell... | 84 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06045910) |
| August 21, 2023 | NCT06002659 | CAR20(NAP)-T Therapy for B Cell Lymphoma (CARMA-01 Study) | Uppsala University | Phase 1/2 | Recruiting | B-cell Lymphoma | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06002659) |
| May 6, 2023 | NCT05842707 | Study of Cord Blood-derived CAR NK Cells Targeting CD19/CD70 in Refractory/Relapsed B-cell Non-Hodgkin Lymphoma | Sponsor not shown (see the record) | Phase 1/2 | Recruiting | Refractory or Relapsed B-cell Non-Hodgkin Lymphoma | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05842707) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| Shenzhen University General Hospital | 3 |
| M.D. Anderson Cancer Center | 2 |
| [AstraZeneca](https://specstream.ai/data/clinical-trials/company/astrazeneca) | 2 |
| Nanjing IASO Biotechnology Co., Ltd. | 1 |
| Instituto de Investigación Biomédica de Salamanca | 1 |
| Uppsala University | 1 |
| University of Colorado, Denver | 1 |
| National Cancer Institute (NCI) | 1 |
| Lyell Immunopharma, Inc. | 1 |
| Cellectis S.A. | 1 |
| Essen Biotech | 1 |
| CRISPR Therapeutics AG | 1 |
| New York Medical College | 1 |
| [Daiichi Sankyo](https://specstream.ai/data/clinical-trials/company/daiichi-sankyo) | 1 |
| Shanghai Tongji Hospital, Tongji University School of Medicine | 1 |
| Chinese PLA General Hospital | 1 |
| [BeOne Medicines](https://specstream.ai/data/clinical-trials/company/beone-medicines) | 1 |
| TORL Biotherapeutics, LLC | 1 |
| [Beijing Biotech](https://specstream.ai/data/clinical-trials/company/beijing-biotech) | 1 |
| Nurix Therapeutics, Inc. | 1 |
| AVM Biotechnology Inc | 1 |
| Step Pharma, SAS | 1 |
| Shanghai Helioson Pharmaceutical Co., Ltd. | 1 |
| Medical University of South Carolina | 1 |
| [Novartis Pharmaceuticals](https://specstream.ai/data/clinical-trials/company/novartis-pharmaceuticals) | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 20 |
| China | 14 |
| Australia | 5 |
| France | 5 |
| Italy | 5 |
| United Kingdom | 5 |
| Spain | 4 |
| South Korea | 4 |
| Japan | 3 |
| Germany | 2 |
| Taiwan | 2 |
| Poland | 2 |
| Sweden | 1 |
| Czechia | 1 |
| Denmark | 1 |
| Brazil | 1 |
| New Zealand | 1 |
| Singapore | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [High schools in the United States](https://specstream.ai/data/businesses/high-schools/united-states)
- [Payroll companies in the United States](https://specstream.ai/data/businesses/payroll-companies/united-states)
- [Trailer rental companies in the United States](https://specstream.ai/data/businesses/trailer-rental-companies/united-states)
- [Brewing supply stores in the United States](https://specstream.ai/data/businesses/brewing-supply-stores/united-states)
- [Fire protection companies in the United States](https://specstream.ai/data/businesses/fire-protection-companies/united-states)
- [Mexican restaurants in the United States](https://specstream.ai/data/businesses/mexican-restaurants/united-states)
